PO

Insulet Corporation (PODD)

HealthcareMedical Devices
151.28USD
-10.14%
Magic Rank
#1103
Earnings Yield
4.0%
Return on Capital
39.2%
Market Cap
11.6B

Performance vs S&P 500 (5Y)

PODD.US
S&P 500

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Magic Formula Analysis

Enterprise Value11.8B
Market / Universe
us
USA

"A company with high ROC and high EY is statistically more likely to outperform the market."

Key Indicators

P/E Ratio48.14
Dividend YieldN/A
Debt to Equity0.16
Gross Margin18.7%